Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Letter: Tralokinumab for the Treatment of Chronic Hand Eczema: A Retrospective Case Series with Long-Term Follow-up. (PubMed, Dermatitis) - No abstract available

Journal • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Phenotype Switching From Atopic Dermatitis To Psoriasiform Dermatitis Following Dupilumab Therapy: Case Report (ACAAI 2025) - "She transitioned to tralokinumab in May 2023 with noted improvement, but it was discontinued due to recurrent respiratory infections. JAK inhibitors such as upadacitinib offer an effective therapeutic strategy for AD and may also benefit psoriasiform features. Genetic factors, namely East Asian ancestry, and IL-23/Th17 pathway activation may underlie this immunologic shift and warrant further investigation."

Case report • Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Respiratory Diseases • IL23A • IL4 • IL4R

Letter: Cost-per-Responder Analysis of Tralokinumab Versus Dupilumab for Moderate-to-Severe Atopic Dermatitis Across Universal Health Care Systems. (PubMed, Dermatitis) - No abstract available

HEOR • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness and safety of tralokinumab in a patient with severe atopic dermatitis and hepatitis B virus. (PubMed, An Bras Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Hepatitis B • Immunology • Infectious Disease • Inflammation

Tralokinumab is effective and well-tolerated in adults with atopic dermatitis with moderate-to-severe hand involvement who are candidates for systemic therapy: Week 16 results from the phase 3b ADHAND trial (ISAD-RAJKA 2025) - P3 | "Rates of reported adverse events (AEs), serious AEs, and AEs leading to withdrawal from trial were low and similar between tralokinumab and PBO. Tralokinumab demonstrated superior efficacy vs PBO across all primary and key secondary endpoints at 16 weeks, with an overall frequency of AEs consistent with PBO, in HandAD patients, offering tralokinumab as a potentially valuable treatment option for this hard-to-treat population."

Clinical • P3 data • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Tralokinumab provides long-term control of head and neck atopic dermatitis: end-of treatment results from the 5-year open-label ECZTEND study (ISAD-RAJKA 2025) - P3 | "In subjects with H&N EASI ≥1 at parent trial baseline, H&N EASI-75 was observed in 84.4% (95%CI: 74.6; 91.0%), H&N EASI =0 in 46.8% (36.0; 57.8%), and H&N EASI ≤1 in 89.6% (80.6; 94.9%) of patients. Tralokinumab provided sustained improvements of H&N AD in patients (≥12 years) continuing treatment for up to 5 years, indicating that tralokinumab is an efficacious long-term option for AD patients with H&N involvement."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Clinical Characteristics and Treatment Pattern Analysis of Severe Atopic Dermatitis Patients Receiving Biologics or JAK Inhibitors: A Single-Center Study (ISAD-RAJKA 2025) - "Among 110 patients, dupilumab (60%) was most commonly prescribed, followed by upadacitinib (20%), baricitinib (14%), and tralokinumab (5.7%)...Higher baseline EASI predicted fast response, while itraconazole administration history was linked to partial response in our study. This study identified clinical features linked to treatment choice in severe atopic dermatitis. Lichenoid phenotype and hand/foot involvement were more often associated with JAK inhibitor use, supporting personalized treatment approaches."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab for the treatment of severe atopic dermatitis: Real- world data from the Czech Republic BIOREP Registry (ISAD-RAJKA 2025) - "Patients with severe AD should be treated with biological drugs (dupilumab, tralokinumab, lebrikizumab) or Janus kinase inhibitors (JAKi), such as abrocitinib, baricitinib, and upadacitinib. Our results also surpassed a recent Japanese real-world study (EASI 75 and EASI90 57.1% and 27.3%). These findings support lebrikizumab as an effective treatment for severe AD."

Real-world • Atopic Dermatitis • CNS Disorders • Conjunctivitis • Dermatitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Sleep Disorder • IL13

Real-world use of systemic treatments for severe atopic dermatitis in France between 2018 and 2023 , using the French claims database (ISAD-RAJKA 2025) - "The treatment of severe atopic dermatitis (AD) has evolved since 2017 with the introduction of the first biologic, dupilumab, followed by tralokinumab. Asthma and cardiovascular history are associated with its prescription. This nationwide study highlights the widespread and sustained use of dupilumab among systemic treatments for AD from 2018 to 2024."

Claims database • Clinical • Real-world • Real-world evidence • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Respiratory Diseases

Real life efficacy and systemic immunomodulation upon anti-IL-13 treatment in atopic dermatitis (ISAD-RAJKA 2025) - "IgE levels decreased by 9.7%; eosinophils remained stable. We determined robust and sustained real life effectiveness of tralokinumab which was associated with a profound systemic immune modulation characterized by a diminished Th2/Th17 activity and an increased Th1/regulatory signature, supporting a disease-modifying effect of this treatment."

Clinical • Immunomodulating • Atopic Dermatitis • Dermatitis • Dermatology • Immune Modulation • Immunology • Pruritus • CD4 • CD8 • IFNG • IL10 • IL13 • IL17A • IL4

Effectiveness of 12-months tralokinumab treatment in 124 adults with atopic dermatitis with genital involvement: Final real-world data from the prospective, non-interventional, international, single-cohort TRACE study (ISAD-RAJKA 2025) - "In a real-world setting, 12-months of tralokinumab treatment improved disease severity and QoL measures in a substantial proportion of adult AD patients with genital involvement, with improvements seen as early as month 3."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Allergy and dermatology US treatment guidelines review for adults with atopic dermatitis. (PubMed, J Allergy Clin Immunol Glob) - "We identified key similarities in the use of newer biologic agents, including dupilumab and tralokinumab. There are differences between the recommendations for topical phosphodiesterase-4 inhibitors, including crisaborole, and both topical and systemic Janus kinase inhibitors, including ruxolitinib, upadacitinib, abrocitinib, and baricitinib...Despite both sets of guidelines being evidence-based, variations in recommendations arise when factoring in patient preferences, perspectives, and risk aversion. As newer treatments become available for patients with AD, it will be important to monitor the evolving concordance or discordance of these guidelines given their direct impact on patient care."

Journal • Allergy • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases

META-ANALYSIS: IMPACT OF BIOLOGIC TREATMENTS ON STEROID REDUCTION, OCS WITHDRAWAL, AND EXACERBATION RATE IMPROVEMENTS IN SEVERE ASTHMA PATIENTS (CHEST 2025) - "6 different biologics (Dupilumab, Tezepelumab, Omalizumab, Reslizumab, Benralizumab and Tralokinumab) were considered in the analysis. This meta-analysis demonstrates significant reductions in steroid use and exacerbation rates, indicating tha steroid-sparing strategies may improve patient outcomes. However, heterogeneity remains a major challenge, which emphasize the need for standardized treatment approaches. While OCS withdrawal trends toward improvement, statistical significance wa not reached."

Retrospective data • Asthma • Immunology • Osteoporosis • Respiratory Diseases • Rheumatology

The role of interleukin-13 in the management of atopic dermatitis: an expert consensus panel. (PubMed, Dermatol Online J) - "Targeted therapies, including interleukin-13 inhibitors, provide rapid, durable, and safe options for managing moderate-to-severe atopic dermatitis. This consensus highlights interleukin-13 inhibition as a cornerstone in advancing atopic dermatitis treatment strategies, offering improved patient outcomes and quality of life."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pain • Pruritus • IL13

Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational Study. (PubMed, Clin Exp Dermatol) - "Though rarely, psoriasis and SpA are AEs emerging during dupilumab or tralokinumab therapy in AD patients. Close monitoring and prompt differential diagnosis is essential to optimize patient outcomes."

Journal • Observational data • Ankylosing Spondylitis • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

PRAC endorsed updates to sections 4.8 and 5.1 of the SmPC for tralokinumab to reflect final clinical efficacy and safety data from the Phase 3 open-label extension PASS study LP0162-1337 (ECZTEND). The study evaluated long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis who had participated in prior tralokinumab trials. (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 1 –4 Sep 2025

PRAC • Atopic Dermatitis • Immunology

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis. (PubMed, Dermatol Ther (Heidelb)) - "Comparable maintenance of efficacy was observed between tralokinumab and lebrikizumab after 52 weeks of treatment among patients meeting response criteria at week 16."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Key data to be presented at the 2025 Fall Clinical Dermatology Conference by LEO Pharma include (Businesswire) - "The first U.S. prevalence data on CHE, based on a survey of more than 10,000 people. The CHECK study includes findings on demographics, disease severity, healthcare resource utilization, and ability to work among CHE patients; New health economics and outcomes data that explores the burden of CHE in the U.S. and analyzes the potential financial impact of ANZUPGO (delgocitinib) cream on a U.S. Commercial Health plan; Real-world ADBRY (tralokinumab-ldrm) data, evaluating the safety and effectiveness of up to 12 months of treatment for patients with moderate to severe AD; New findings examining the burden of GPP in the U.S., as well as the effect of treatments such as SPEVIGO (spesolimab)."

Clinical data • Atopic Dermatitis • Pustular Psoriasis

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. (PubMed, Am J Clin Dermatol) - P3 | "Tralokinumab was well-tolerated and improved signs, symptoms, and biomarkers in patients with moderate-to-severe AD at 16 weeks across the racial subgroups studied, with further improvement in response rates up to 2 years of treatment."

Journal • P3 data • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis. (PubMed, Dermatol Ther (Heidelb)) - P3 | "In France, Germany, Italy, UK, and Canada, tralokinumab in combination with TCS may be more cost-effective for moderate-to-severe AD than dupilumab in combination with TCS at week 32 for EASI-75 and IGA-0/1 responders. The difference in cost-effectiveness depends on the efficacy and cost of the treatments and on the proportion of patients treated with tralokinumab who switch per label from Q2W to Q4W, which additionally reduces treatment cost."

HEOR • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long-Term Treatment With Dupilumab: A Single-Center Retrospective Study. (PubMed, J Dermatol) - No abstract available

Clinical data • Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Letter: Real-World 48-Week Outcomes of Tralokinumab Treatment for Prurigo Nodularis-Like Atopic Dermatitis: A Japanese Retrospective Study. (PubMed, Dermatitis) - No abstract available

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis

Sustained and rapid efficacy of abrocitinib in atopic dermatitis: A multicenter real-world study with 48-Week follow-up (EADV 2025) - "Prior treatments included ciclosporin 93.9% (46/49), methotrexate 22.4% (11/49), phototherapy 20.4% (10/49), dupilumab 28.6% (14/49), tralokinumab 26.5% (13/49), upadacitinib 16.3% (8/49), and baricitinib 6.1% (3/49). Abrocitinib demonstrated rapid and sustained efficacy in the treatment of atopic dermatitis in a real-world, multicenter cohort, with meaningful clinical improvements evident by week 4 and largely maintained through week 48."

Clinical • Real-world • Real-world evidence • Allergic Rhinitis • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Respiratory Diseases

Factors influencing the decision over systemic therapy and goals of therapy for atopic dermatitis (EADV 2025) - " Current guidelines and systematic reviews support the safety and efficacy of systemic therapy including conventional drugs (cyclosporine, methotrexate, and azathioprine), biologics (dupilumab and tralokinumab), and JAK inhibitors (baricitinib, upadacitinib, and abrocitinib) recommended for treating moderate and severe AD. Recently, additional biologics have been evaluated in clinical trials, including lebrikizumab, nemolizumab, eblasakimab, and OX40/OX40L, among others.Thus, AD patient management and decisions regarding advanced/systemic therapy are complex-requiring the consideration of multiple disease-related factors: disease severity, patient medical history and comorbidities, previous topical therapy use, patient preferences, expectations and fears, pregnancy planning, impact on related risks and any associated psychological or psychiatric issues. Available data indicate the importance of a personalized, stepwise, and multidisciplinary approach which promotes..."

Atopic Dermatitis • CNS Disorders • Depression • Dermatitis • Dermatology • Immunology • Mood Disorders • Psychiatry • Suicidal Ideation • TNFSF4

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK inhibitors in the BioDay Registry (EADV 2025) - "In this prospective, multicenter cohort, dupilumab had the highest overall DS, followed by upadacitinib, tralokinumab, and abrocitinib, with baricitinib showing the lowest DS rates. Ineffectiveness was the main reason for treatment discontinuation across all therapies. Dupilumab consistently showed superior DS in both naïve and experienced subgroups."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases